Peters G J, van Dijk J, Laurensse E, van Groeningen C J, Lankelma J, Leyva A, Nadal J C, Pinedo H M
Department of Oncology, Free University Hospital, Amsterdam, The Netherlands.
Br J Cancer. 1988 Mar;57(3):259-65. doi: 10.1038/bjc.1988.56.
The effect of delayed uridine administration on the in vitro growth inhibitory effects of 5-fluorouracil (5FU) and on the in vivo antitumour activity and toxicity was studied. In vitro growth inhibition of the human intestinal cell lines WiDr and Intestine 407 by 3 microM 5FU could be reversed by 1.0 mM uridine; the effect was more pronounced with WiDr cells. At 0.1 mM uridine an intermediate effect was observed. Inhibition of colony formation in both cell lines could also be reversed by delayed administration of uridine at 0.1 and 1 mM. Incorporation of 5FU into RNA of WiDr cells did not proceed after addition of uridine, in contrast to Intestine 407 cells. In these cells only a partial inhibition was observed. In vivo we studied the effect of uridine on two colon carcinoma tumour lines, the 5FU sensitive Colon 38 and the relatively resistant Colon 26. 5FU was administered i.p. in a weekly schedule. With Colon 26 delayed administration of uridine (3500 mg kg-1) at 2 and 20 h after 5FU enabled us to increase the 5FU dose from 100 to 250 300mg kg-1. The combination of high-dose 5FU and uridine resulted both in a superior antitumour effect and an increase in life span. In the 5FU sensitive Colon 38 we determined whether the sensitivity to 5FU was affected by uridine. Mice were treated at the non-lethal dose of 100 mg kg-1 which inhibited tumour growth almost completely. Delayed administration of uridine did not significantly affect the antitumour effect. In non-tumour bearing mice we studied the time course of the reversal of the haematological toxicity of 5FU. The effective dose of 100 mg kg-1 induced a significant decrease in leukocytes; in combination with delayed uridine the leukopenia was less severe and recovered more rapidly. 5FU also induced a decrease in haematocrit, which could be prevented by delayed administration of uridine. In conclusion, in cell culture the reversal of 5FU cytotoxicity could be achieved at a low concentration of 0.1 mM uridine, the extent of the reversal might be related to the 5FU incorporation into RNA. In vivo the relatively resistant tumour Colon 26 could be treated with a higher dose of 5FU in the presence of uridine. The sensitivity to 5FU of the sensitive Colon 38 was not affected by delayed administration of uridine, while the haematological toxicity of 5FU was less. So, delayed administration of uridine after 5FU resulted in an improved therapeutic effect in both a relatively resistant and sensitive tumour.
研究了延迟给予尿苷对5-氟尿嘧啶(5FU)体外生长抑制作用以及体内抗肿瘤活性和毒性的影响。3 microM 5FU对人肠道细胞系WiDr和Intestine 407的体外生长抑制作用可被1.0 mM尿苷逆转;对WiDr细胞的作用更明显。在0.1 mM尿苷时观察到中等程度的作用。0.1 mM和1 mM的尿苷延迟给药也可逆转这两种细胞系中的集落形成抑制。与Intestine 407细胞相反,在加入尿苷后,5FU不再掺入WiDr细胞的RNA中。在这些细胞中仅观察到部分抑制。在体内,我们研究了尿苷对两种结肠癌肿瘤系的影响,5FU敏感的Colon 38和相对耐药的Colon 26。5FU按每周一次的方案腹腔注射。对于Colon 26,在5FU给药后2小时和20小时延迟给予尿苷(3500 mg kg-1)使我们能够将5FU剂量从100增加到250或300mg kg-1。高剂量5FU与尿苷的联合使用既产生了更好的抗肿瘤效果,又延长了生存期。在5FU敏感的Colon 38中,我们确定尿苷是否会影响对5FU的敏感性。以100 mg kg-1的非致死剂量治疗小鼠,该剂量几乎完全抑制肿瘤生长。尿苷延迟给药对抗肿瘤效果没有显著影响。在无肿瘤小鼠中,我们研究了5FU血液学毒性逆转的时间进程。100 mg kg-1的有效剂量导致白细胞显著减少;与延迟给予尿苷联合使用时,白细胞减少不那么严重且恢复更快。5FU还导致血细胞比容降低,这可通过延迟给予尿苷来预防。总之,在细胞培养中,0.1 mM的低浓度尿苷即可实现5FU细胞毒性的逆转,逆转程度可能与5FU掺入RNA有关。在体内,在尿苷存在的情况下,相对耐药的肿瘤Colon 26可用更高剂量的5FU治疗。延迟给予尿苷不影响敏感的Colon 38对5FU的敏感性,同时5FU的血液学毒性较小。因此,5FU后延迟给予尿苷在相对耐药和敏感的肿瘤中均产生了改善的治疗效果。